Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Systemic consequences and co-morbidity
- What is COPD?
- What is a co-morbidity?
- Comorbid diagnoses and symptoms in COPD
- Co-morbidity in COPD (1)
- More common than...
- Some common comorbidities in COPD patients
- Lung cancer, COPD and smoking
- Clinical importance of assessing co-morbidity
- Why co-morbidity is important
- COPD affects co-morbidity
- Co-morbidity affects COPD
- Exacerbation susceptibility
- GORD in COPD
- COPD & co-morbidity: a reciprocal relationship
- Mechanisms of co-morbidity in COPD
- Co-morbidity in COPD (2)
- COP(D) and ageing
- Co-morbidity in COPD (3)
- Mechanisms
- Questions
- Systemic inflammation and vascular risk
- RA and vascular risk
- COPD: systemic inflammation
- Systemic and airway inflammation in COPD
- Systemic inflammation at exacerbation of COPD
- COPD and MI risk (1)
- COPD and MI risk (2)
- Management of co-morbidity in COPD
- Principles
- UK NICE guidance
- GOLD: COPD and co-morbidities
- Conclusion
- Thank you
Topics Covered
- COPD is associated with multiple systemic co-morbidities including increased cardiovascular risk, osteoporosis, metabolic disturbance, and skeletal muscle dysfunction
- The importance of assessing co-morbidity in COPD
- The mechanisms of interaction between COPD and co-morbidities
- How to manage co-morbidity in a patient with COPD
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hurst, J. (2012, August 1). Managing co-morbidity in COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 5, 2024, from https://doi.org/10.69645/YMSC2721.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. John Hurst has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.